Early Response Seen With Teprotumumab for TED Appears to Wane in the Long Term
- Posted on: Aug 6 2024
- Leave a response
Investigators studied the long-term proptosis reactivation/recurrence rate in patients who had completed a full course of teprotumumab treatment for active thyroid eye disease (TED).
Source: AAO
Posted in: Uncategorized
